

A Comparison of Two LDL Cholesterol Targets after Isch

New England Journal of Medicine

382, 9-19

DOI: [10.1056/nejmoa1910355](https://doi.org/10.1056/nejmoa1910355)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Statins and Stroke – It’s Complicated. <i>New England Journal of Medicine</i> , 2020, 382, 81-82.	13.9	12
4	A lower LDL-C target is better after stroke. <i>Nature Reviews Cardiology</i> , 2020, 17, 70-70.	6.1	1
5	Management of Acute Ischemic Stroke. <i>Critical Care Medicine</i> , 2020, 48, 1654-1663.	0.4	316
6	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	1.4	22
7	Evaluating the utility of fasting lipid panel in addition to random lipid panel in determining lipid-lowering therapy in acute ischemic stroke or TIA patients. <i>Clinical Neurology and Neurosurgery</i> , 2020, 197, 106068.	0.6	0
9	Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. <i>Annals of Translational Medicine</i> , 2020, 8, 1265-1265.	0.7	11
10	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020, 51, 3504-3513.	1.0	67
11	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021, 16, 738-750.	2.9	11
12	Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3796.	1.0	4
13	Management of carotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a critical review. <i>European Heart Journal Supplements</i> , 2020, 22, M35-M42.	0.0	43
15	Inflammation of carotid plaques and risk of cerebrovascular events. <i>Annals of Translational Medicine</i> , 2020, 8, 1281-1281.	0.7	18
16	Statin Controversies Continued: Response to the Letter from Azemawah et al.. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 887-888.	1.3	0
17	New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. <i>JAMA Neurology</i> , 2020, 77, 1308.	4.5	20
18	Risk Factor Control in Stroke Survivors with Diagnosed and Undiagnosed Diabetes: A Ghanaian Registry Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105304.	0.7	6
19	Stroke Prevention in Older Adults. <i>Stroke</i> , 2020, 51, 3770-3777.	1.0	19
20	Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. <i>Stroke</i> , 2020, 51, 2960-2971.	1.0	19
22	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3613-3682.	1.8	63
24	Prevention of Stroke by Lowering Blood Cholesterol Concentrations. , 2020, , 297-307.		0

#	ARTICLE	IF	CITATIONS
25	Secondary prevention among uninsured stroke patients: A free clinic study. SAGE Open Medicine, 2020, 8, 205031212096532.	0.7	3
26	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	6.3	167
27	Transient Ischemic Attack. New England Journal of Medicine, 2020, 382, 1933-1941.	13.9	49
28	Low-density lipoprotein cholesterol and stroke: How low should we go?. Journal of Diabetes Investigation, 2020, 11, 1379-1381.	1.1	1
29	Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey. Lipids in Health and Disease, 2020, 19, 131.	1.2	5
30	Use of statins for the secondary prevention of stroke: are we respecting the scientific evidences?. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104912.	0.7	1
31	The LDL cholesterol in stroke limbo. Current Opinion in Lipidology, 2020, 31, 161-162.	1.2	1
32	Current Status of Dyslipidemia Treatment for Stroke Prevention. Current Neurology and Neuroscience Reports, 2020, 20, 31.	2.0	11
33	LDL (Low-Density Lipoprotein) Cholesterol Below 70. Stroke, 2020, 51, 2276-2278.	1.0	1
34	Prior Stroke in PFO Patients Is Associated With Both PFO-Related and -Unrelated Factors. Frontiers in Neurology, 2020, 11, 503.	1.1	2
35	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. Current Cardiology Reports, 2020, 22, 66.	1.3	26
36	Aggiornamenti in tema di malattia cerebrovascolare: prevenzione, terapia e riabilitazione. Italian Journal of Medicine, 2020, , 1-174.	0.2	1
37	Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories. Journal of the American College of Cardiology, 2020, 75, 2110-2118.	1.2	27
38	Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin. Circulation, 2020, 142, 748-757.	1.6	21
39	Management of Symptomatic Intracranial Atherosclerotic Stenosis. Current Treatment Options in Neurology, 2020, 22, 1.	0.7	0
40	Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease. American Journal of Cardiology, 2020, 128, 28-34.	0.7	3
41	Stroke. Lancet, The, 2020, 396, 129-142.	6.3	533
43	Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke. Stroke, 2020, 51, 1231-1239.	1.0	39

#	ARTICLE	IF	CITATIONS
44	Oxidized low-density lipoprotein (LDL) and LDL cholesterol are associated with outcomes of minor stroke and TIA. <i>Atherosclerosis</i> , 2020, 297, 74-80.	0.4	16
45	In stroke patients, lower LDL-cholesterol is actually better. <i>European Journal of Internal Medicine</i> , 2020, 75, 117-118.	1.0	0
46	Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 3.	2.0	6
47	Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options. <i>Advances in Therapy</i> , 2020, 37, 1829-1865.	1.3	20
48	Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1804-1818.	1.2	189
49	Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2119-2121.	1.2	20
50	LDL Cholesterol Targets after Ischemic Stroke. <i>New England Journal of Medicine</i> , 2020, 382, 1480-1481.	13.9	15
51	PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention. <i>Stroke</i> , 2020, 51, 1361-1362.	1.0	3
52	Biotechnology Approaches for the Treatment of Dyslipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 167-183.	1.3	4
53	LDL Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2021, 134, 507-513.	0.6	6
54	Current characteristics and early functional outcome of older stroke patients: a population-based study (Dijon Stroke Registry). <i>Age and Ageing</i> , 2021, 50, 898-905.	0.7	16
55	Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. <i>Neurology</i> , 2021, 96, e54-e66.	1.5	15
56	Prevalence, prognosis, and treatment of atherosclerotic intracranial stenosis in Caucasians. <i>International Journal of Stroke</i> , 2021, 16, 248-264.	2.9	18
57	Should we treat high LDL cholesterol in "healthy" elderly individuals?. <i>Atherosclerosis</i> , 2021, 317, 50-51.	0.4	5
58	Cost-Effectiveness of Using LDL-Direct Versus Lipid-Panel as Part of the Inpatient Stroke Workup. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105417.	0.7	0
59	Important advances in stroke research in 2020. <i>Lancet Neurology</i> , The, 2021, 20, 2-3.	4.9	2
60	Dementia research in 2020: moving forward despite the COVID-19 pandemic. <i>Lancet Neurology</i> , The, 2021, 20, 3-5.	4.9	3
61	How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. <i>European Heart Journal</i> , 2021, 42, 2154-2169.	1.0	28

#	ARTICLE	IF	CITATIONS
62	Benefits of LDL cholesterol reduction in the secondary prevention of ischemic stroke New evidence. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2021, 33, 53-54.	0.1	0
63	Dyslipidemia and Hemorrhagic Stroke. <i>Stroke Revisited</i> , 2021, , 43-54.	0.2	0
64	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	1.0	92
65	Practical Management of Dyslipidemia in Stroke Patients. <i>Stroke Revisited</i> , 2021, , 155-163.	0.2	0
66	Should We Target Global Risk or Risk Factors?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 2.	2.0	2
67	Stroke and diets �� A review. <i>Tzu Chi Medical Journal</i> , 2021, 33, 238.	0.4	7
68	Aortic Sources of Embolism. <i>Frontiers in Neurology</i> , 2020, 11, 606663.	1.1	18
69	Endovascular Stent Grafting for Recurrent Strokes Due to Fragile Innominate Artery Plaque: A Case Report. <i>NMC Case Report Journal</i> , 2021, 8, 21-25.	0.2	0
70	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. <i>Journal of Clinical Medicine</i> , 2021, 10, 886.	1.0	5
72	Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020. <i>Endocrinology and Metabolism</i> , 2021, 36, 41-50.	1.3	4
74	Use of ADAM�� and CHA2DS2��VASC scores to predict complex aortic atheroma after brain ischemia: A prospective observational study. <i>Echocardiography</i> , 2021, 38, 612-622.	0.3	0
76	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2021, 33, 85-107.	0.1	4
77	Lipid Lowering Drugs: Present Status and Future Developments. <i>Current Atherosclerosis Reports</i> , 2021, 23, 17.	2.0	41
79	Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 85, 130-132.	1.0	7
80	Comentario del CEIPV a la actualizaci�n de las Gu�as Europeas de Prevenci�n Vascular en la Pr�ctica Cl�nica. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2021, 33, 85-107.	0.4	1
81	Statin treatment and outcomes after embolic stroke of undetermined source. <i>Internal and Emergency Medicine</i> , 2021, 16, 1261-1266.	1.0	5
83	Evolving ischemic stroke subtypes in 15 years: A hospital-based observational study. <i>International Journal of Stroke</i> , 2022, 17, 444-454.	2.9	7
84	Current approach to acute stroke management. <i>Internal Medicine Journal</i> , 2021, 51, 481-487.	0.5	10

#	ARTICLE	IF	CITATIONS
86	Clinical perspectives on ischemic stroke. <i>Experimental Neurology</i> , 2021, 338, 113599.	2.0	14
87	Statins After Ischemic Stroke in the Oldest. <i>Stroke</i> , 2021, 52, 1244-1252.	1.0	5
88	Statins in patients with acute ischemic stroke: when we should start therapy?. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 16-28.	0.1	4
89	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.4	83
90	Role of Blood Lipid Levels and Lipid-Lowering Therapy in Stroke Patients with Different Levels of Cerebral Artery Diseases: Reconsidering Recent Stroke Guidelines. <i>Journal of Stroke</i> , 2021, 23, 149-161.	1.4	16
91	Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 793-806.	1.3	8
92	Lacunar stroke: mechanisms and therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 823-830.	0.9	27
93	Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. <i>Diabetes</i> , 2021, 70, 1807-1815.	0.3	0
94	Metabolic Reprogramming: Strategy for Ischemic Stroke Treatment by Ischemic Preconditioning. <i>Biology</i> , 2021, 10, 424.	1.3	10
95	Acetaldehyde Dehydrogenase 2 regulates HMG-CoA reductase stability and cholesterol synthesis in the liver. <i>Redox Biology</i> , 2021, 41, 101919.	3.9	27
96	The Clinical Approach to Stroke in Young Adults. , 0, , 53-78.		3
97	Effects of an Avocado-based Mediterranean Diet on Serum Lipids for Secondary Prevention after Ischemic Stroke Trial (ADD-SPISE). <i>Medicine (United States)</i> , 2021, 100, e26425.	0.4	0
98	Lipid Levels and 3-Month Prognosis After Spontaneous Intracerebral Hemorrhage in Women. <i>Frontiers in Neurology</i> , 2021, 12, 690194.	1.1	3
99	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 315-337.	0.3	57
100	Drugs in secondary stroke prevention. <i>Australian Prescriber</i> , 2021, 44, 85-90.	0.5	6
103	Cardiovascular MRI Compared to Echocardiography to Identify Cardioaortic Sources of Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 699838.	1.1	8
104	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2020. <i>American Journal of Medicine</i> , 2021, 134, 854-859.	0.6	1
105	LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project. <i>European Heart Journal</i> , 2021, 42, 3175-3186.	1.0	14

#	ARTICLE	IF	CITATIONS
106	Multistate analysis of multitype recurrent event and failure time data with event feedbacks in biomarkers. <i>Scandinavian Journal of Statistics</i> , 0, , .	0.9	1
107	Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targetsâ€™ attainment in subjects with and without type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 144.	2.7	17
108	Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies. <i>JAMA Neurology</i> , 2021, 78, 809.	4.5	32
109	The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8074.	1.8	71
110	Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?. <i>Current Cardiology Reports</i> , 2021, 23, 116.	1.3	2
111	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	1.0	1,123
112	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
113	Lowâ€™Density Lipoprotein Cholesterol and Risk of Recurrent Vascular Events in Chinese Patients With Ischemic Stroke With and Without Significant Atherosclerosis. <i>Journal of the American Heart Association</i> , 2021, 10, e021855.	1.6	6
114	A spark of hope: histopathological and functional recovery after critical COVID-19. <i>Infection</i> , 2022, 50, 263-267.	2.3	5
115	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	0.8	367
116	The prognostic significance of the lipid profile after an ischemic stroke. <i>Neurological Research</i> , 2022, 44, 139-145.	0.6	5
117	Guideline-directed low-density lipoprotein management in high-risk ischemic stroke or transient ischemic attack admissions in China from 2015 to 2019. <i>Annals of Translational Medicine</i> , 2021, 9, 1224-1224.	0.7	0
118	Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2021, 52, 2521-2529.	1.0	5
119	Ischemic Stroke. <i>American Journal of Medicine</i> , 2021, 134, 1457-1464.	0.6	247
120	Cardiovascular Disease in Patients with Diabetes: a Comparison of Professional Society Guidelines. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	0
121	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
122	La prÃ©vention secondaire mÃ©dicamenteuse en pathologie neuro-vasculaire a-t-elle des spÃ©cificitÃ©s?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2021, 205, 1091-1091.	0.0	0
123	Colchicine Use and Risks of Stroke Recurrence in Acute Non-Cardiogenic Ischemic Stroke Patients: A Population-Based Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 935.	1.1	5

#	ARTICLE	IF	CITATIONS
124	Emerging agents for the treatment and prevention of stroke: progress in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1025-1035.	1.9	13
125	Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2022, 53, 79-86.	1.0	11
126	Inflammation, Cholesterol, and Stroke Risk: Building Evidence for a Dual Target Strategy for Secondary Prevention. <i>Stroke</i> , 2021, 52, 2837-2838.	1.0	1
127	Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source. <i>Frontiers in Neurology</i> , 2021, 12, 719329.	1.1	20
128	Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients. <i>Stroke</i> , 2021, 52, 2827-2836.	1.0	27
129	Effects of Anticoagulation on Low-Density Lipoprotein-Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2021, 134, e533.	0.6	0
130	Letter to the Editor: Higher dose statins after stroke. <i>Australian Prescriber</i> , 2021, 44, 146-147.	0.5	0
131	Stroke Prevention After Intracerebral Hemorrhage: Where Are We Now?. <i>Current Cardiology Reports</i> , 2021, 23, 162.	1.3	2
132	Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 106057.	0.7	8
133	Protein energy wasting-based nutritional assessment predicts outcomes of acute ischemic stroke and solves the epidemiologic paradox. <i>Nutrition</i> , 2022, 93, 111431.	1.1	3
134	Beneficios de la reducci3n del colesterol LDL en la prevenci3n secundaria del ictus isqu3mico. <i>Nuevas evidencias. Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 53-54.	0.4	1
136	Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 2001-2009.	0.8	10
137	Recent updates in dyslipidemia management: perspectives in stroke-specific situation. <i>Precision and Future Medicine</i> , 2020, 4, 9-20.	0.5	3
138	Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (≥75 years old). <i>Endocrine</i> , 2022, 75, 418-426.	1.1	7
139	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	2.6	28
142	Usefulness of carotid ultrasonography and treatment of carotid disease. <i>Journal of the Korean Medical Association</i> , 2020, 63, 342-353.	0.1	1
143	Trends and controversies in carotid artery stenosis treatment. <i>F1000Research</i> , 2020, 9, 940.	0.8	5
144	Recent advances in preventing recurrent stroke. <i>F1000Research</i> , 2020, 9, 1012.	0.8	1

#	ARTICLE	IF	CITATIONS
145	High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 760926.	1.1	3
146	Secondary Stroke Prevention and Management for the Neuro-Ophthalmologist. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 463-471.	0.4	0
147	Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106141.	0.7	4
148	MECHANISM OF AN ACUTE INCREASE OF INTRACRANIAL PRESSURE AND ITS HARMFUL INFLUENCE ON BRAIN TISSUE. <i>Nejrohirurgi i Nevrologi Kazahstana</i> , 2020, , 3-18.	0.0	0
149	Importance du cholest�rol et de son traitement dans la pr�vention de lâ€™AVC. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2020, 204, 283-291.	0.0	0
150	Medical Treatment. , 2021, , 165-175.		0
151	Impact of Prior Ischemic Stroke on Outcomes in Patients With Heart Failure������ A Propensity-Matched Study ��. <i>Circulation Journal</i> , 2020, 84, 1797-1806.	0.7	3
154	Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol. <i>BJGP Open</i> , 2021, 5, bjgpopen20X101127.	0.9	3
155	The frontiers of acute stroke management. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 2020, 20, .	0.1	0
156	The association between serine hydroxymethyl transferase 1 gene hypermethylation and ischemic stroke. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 454-460.	0.6	0
157	Inpatient Management of Acute Stroke and Transient Ischemic Attack. <i>Neurologic Clinics</i> , 2022, 40, 33-43.	0.8	1
158	Epidemiology of stroke and transient ischemic attacks in the population of the territories adjacent to the former Semipalatinsk Nuclear Test Site, Kazakhstan. <i>Radiation and Environmental Biophysics</i> , 2022, 61, 17-28.	0.6	5
159	Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. <i>Current Vascular Pharmacology</i> , 2021, 19, .	0.8	1
160	High Sensitivity C-Reactive Protein Increases the Risk of Carotid Plaque Instability in Male Dyslipidemic Patients. <i>Diagnostics</i> , 2021, 11, 2117.	1.3	3
161	Cerebrovascular Disease and Statins. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 778740.	1.1	8
162	10th Anniversary of Asia Pacific Stroke Organization: State of Stroke Care and Stroke Research in the Asia Pacific. <i>Cerebrovascular Diseases Extra</i> , 2021, , .	0.5	0
163	Medical Therapy for Ischemic Stroke : Current State and Problems. <i>Japanese Journal of Neurosurgery</i> , 2021, 30, 778-784.	0.0	0
164	The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1634-1645.	0.9	3

#	ARTICLE	IF	CITATIONS
165	Review of the Protective Effects of Statins on Cognition. <i>Cardiology in Review</i> , 2020, Publish Ahead of Print, 328-335.	0.6	3
166	The association between serine hydroxymethyl transferase 1 gene hypermethylation and ischemic stroke. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 454-460.	0.6	2
168	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
169	Heart Disease and Stroke Statisticsâ€™2022 Update: A Report From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001052.	1.6	2,561
170	Transient Ischemic Attack. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2022, , 157-169.	0.3	0
171	The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?. <i>Journal of Clinical Medicine</i> , 2022, 11, 536.	1.0	7
172	Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation before Catheter Ablation and Cardioversion: Risk Factors beyond the CHA2DS2-VASc Score. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 46.	0.8	4
173	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. <i>NeurologÃa (English Edition)</i> , 2022, 37, 61-72.	0.2	2
174	Association of major blood lipids with postâ€stroke dementia: A communityâ€based cohort study. <i>European Journal of Neurology</i> , 2022, 29, 968-979.	1.7	2
175	Intracranial Hemorrhage in the TST Trial. <i>Stroke</i> , 2022, 53, 457-462.	1.0	14
176	What is the Optimal Low-Density Lipoprotein Cholesterol?. <i>Medical Clinics of North America</i> , 2022, 106, 285-298.	1.1	2
177	Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. <i>International Journal of Epidemiology</i> , 2022, 51, 1178-1189.	0.9	5
179	Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. <i>Lancet Neurology</i> , The, 2022, 21, 355-368.	4.9	89
180	Estimated Cardiovascular Benefits of Bempedoic Acid in Patients with Established Cardiovascular Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
181	Self-reported medication adherence and pharmacy refill adherence among persons with ischemic stroke: a cross-sectional study. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 869-877.	0.8	4
182	Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention. <i>JAMA Neurology</i> , 2022, 79, 349.	4.5	39
183	Low-Density Lipoprotein Cholesterol Level After a Strokeâ€Reducing It by Any Means. <i>JAMA Neurology</i> , 2022, , .	4.5	0
184	Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory. <i>Neurology</i> , 2022, 98, 486-498.	1.5	46

#	ARTICLE	IF	CITATIONS
185	Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin. <i>Neurology</i> , 2022, 98, .	1.5	7
186	Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence. <i>Brain</i> , 2022, 145, 457-475.	3.7	54
187	Dual versus mono antiplatelet therapy in mild to moderate stroke during hospitalization. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 506-514.	1.7	3
188	Association between the Suita Score and Stroke Recurrence in Patients with First-ever Ischemic Stroke: A Prospective Cohort Study. <i>Internal Medicine</i> , 2022, 61, 773-780.	0.3	1
189	2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1363-1370.	0.8	5
190	Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	2
191	Sustained low-density lipoprotein cholesterol $\leq 70\text{ mg/dl}$ is associated with improved cardiovascular outcomes in the clinical setting. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13732.	1.7	3
192	Who Will Own the Responsibility to Prescribe Statins? Tragedy of the Commons. <i>JAMA Network Open</i> , 2021, 4, e2137605.	2.8	2
193	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 429.e1-429.e104.	0.6	27
194	Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, 101161CIRCOUTCOMES121008552.	0.9	21
195	Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment. <i>Open Heart</i> , 2022, 9, e001972.	0.9	2
196	LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA. <i>Stroke and Vascular Neurology</i> , 2022, 7, 276-284.	1.5	10
197	Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement. <i>Cardiology Research and Practice</i> , 2022, 2022, 1-7.	0.5	1
198	Hypertension and dyslipidemia treatment in stroke. <i>Vnitřni Lekarstvi</i> , 2022, 68, 172-177.	0.1	1
199	European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. <i>European Stroke Journal</i> , 2022, 7, I-XLI.	2.7	51
200	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2022, 43, 2442-2460.	1.0	43
201	Living clinical guidelines for stroke: updates, challenges and opportunities. <i>Medical Journal of Australia</i> , 2022, 216, 510-514.	0.8	5
202	Lipid-Modifying Therapies and Stroke Prevention. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 375-382.	2.0	7

#	ARTICLE	IF	CITATIONS
203	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	1.3	6
205	Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2022, 122, 7.	0.1	3
207	Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE). <i>Journal of Stroke</i> , 2022, 24, 224-235.	1.4	14
208	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. <i>Atherosclerosis Plus</i> , 2022, 49, 20-27.	0.3	4
209	Editor's Choice "European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, 65, 7-111.	0.8	190
210	Peripheral Organ Injury After Stroke. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
211	Serum zinc levels are associated with obesity and low-density lipoprotein cholesterol in Mexican adults. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 73, 127002.	1.5	9
212	Association of PCSK9 levels and genetic polymorphisms with stroke recurrence and functional outcome after acute ischemic stroke. <i>Annals of Translational Medicine</i> , 2022, 10, 729-729.	0.7	1
213	Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. <i>Stroke</i> , 2022, 53, 2161-2170.	1.0	11
214	Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	4
215	Cardiovascular Events After Intracerebral Hemorrhage. <i>Stroke</i> , 2022, 53, 2131-2141.	1.0	19
216	Extra-Cranial Carotid Artery Stenosis: An Objective Analysis of the Available Evidence. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	13
218	Regarding the new ESO guideline on pharmacological interventions for long-term secondary prevention after ischemic stroke or transient ischemic attack: Current evidence does not allow simplified recommendations. <i>European Stroke Journal</i> , 2022, 7, 339-340.	2.7	0
220	Racial and Ethnic Differences in the Association Between Classical Cardiovascular Risk Factors and Common Carotid Intima-Media Thickness: An Individual Participant Data Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	6
221	Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. , 2022, 1, 25-29.		2
223	Management of Dyslipidemia after Stroke. <i>Journal of the Korean Neurological Association</i> , 2022, 40, 217-227.	0.0	1
224	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan"2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
225	Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2023, 81, 35-44.	0.8	2

#	ARTICLE	IF	CITATIONS
226	Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study. <i>Lancet Neurology</i> , The, 2022, 21, 889-898.	4.9	14
227	The Association of Remnant Cholesterol with Endothelial Dysfunction and Subclinical Atherosclerosis in a Check-Up Population in China. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 684-697.	0.9	4
228	Dual vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack with evidence of large artery atherosclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
230	Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial. <i>Stroke</i> , 2022, 53, 3260-3267.	1.0	9
231	Is It About the Destination or About the Journey?. <i>Stroke</i> , 2022, 53, 3268-3269.	1.0	1
232	A Decade On: The Evolving Renaissance in Intracranial Atherosclerotic Disease. , 2022, 2, .		3
233	Rapid recommendations. <i>Canadian Family Physician</i> , 2022, 68, 664-666.	0.1	1
234	Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10221.	1.8	2
235	Low LDL-C level and intracranial haemorrhage risk after ischaemic stroke: a prospective cohort study. <i>Stroke and Vascular Neurology</i> , 2023, 8, 127-133.	1.5	1
236	Differential influences of LDL cholesterol on functional outcomes after intravenous thrombolysis according to prestroke statin use. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
237	Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
238	Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis. <i>Medicina (Lithuania)</i> , 2022, 58, 1665.	0.8	8
239	Hypolipidemic agents in the secondary prevention of the stroke. , 2022, 1, 96-102.		0
240	Editorial: minor stroke is not minor. <i>Stroke and Vascular Neurology</i> , 2023, 8, 175-177.	1.5	2
241	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	11
243	A single-center pilot randomized controlled trial of atorvastatin loading for preventing ischemic brain damage after carotid artery stenting. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	0
245	Cerebrovascular Disease and Stroke. , 2023, , 1-26.		0
246	Data analysis methods for evaluating cardiovascular disease in patients. <i>Measurement: Sensors</i> , 2023, 25, 100674.	1.3	0

#	ARTICLE	IF	CITATIONS
247	Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 59-71.	1.8	2
248	Heart Disease and Stroke Statisticsâ€™2023 Update: A Report From the American Heart Association. <i>Circulation</i> , 2023, 147, .	1.6	2,130
249	Poststroke Cardiovascular Management: Current Concepts, Integrated Care, and Future Developments. <i>Current Problems in Cardiology</i> , 2023, 48, 101738.	1.1	0
250	Shear stress and plaque microenvironment induce heterogeneity: A multiscale microenvironment evolution model. <i>Computer Methods and Programs in Biomedicine</i> , 2023, 235, 107514.	2.6	0
251	Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. <i>American Journal of Preventive Cardiology</i> , 2023, 14, 100491.	1.3	0
252	A multicenter, prospective, randomized controlled trial of intracranial hemorrhage risk of intensive statin therapy in patients with acute ischemic stroke combined with cerebral microbleeds (CHRISTMAS): Study protocol. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
253	Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients. <i>CJC Open</i> , 2023, 5, 357-363.	0.7	1
254	Pharmacological therapy in the secondary prevention of ischemic stroke in the oldest-old patients: has it improved in recent decades?. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2023, 223, 202-208.	0.3	0
256	Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1078.	3.8	16
257	Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy. <i>Biomedicines</i> , 2023, 11, 798.	1.4	7
258	Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III. <i>BMJ Open</i> , 2023, 13, e069465.	0.8	1
259	Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study. <i>Lancet Neurology</i> , The, 2023, 22, 320-329.	4.9	6
260	Disparate statin prescribing following hospital discharge for stroke or transient ischemic attack: Findings from <scp>COMPASS</scp>. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 2476-2484.	1.3	0
261	Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. <i>Pharmacological Research</i> , 2023, 190, 106738.	3.1	1
262	Large Vessel Occlusion Stroke due to Intracranial Atherosclerotic Disease: Identification, Medical and Interventional Treatment, and Outcomes. <i>Stroke</i> , 2023, 54, 1695-1705.	1.0	15
263	miR-33a and Its Association with Lipid Profile in Patients with Carotid Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6376.	1.8	1
264	The effect of intensive statin therapy in non-symptomatic intracranial arteries: The STAMINA-MRI sub-study. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	0
265	Lipid-Lowering Therapy in the Elderly. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1350-1352.	1.2	2

#	ARTICLE	IF	CITATIONS
266	Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial. <i>Journal of Stroke</i> , 0, , .	1.4	0
267	Diagnosis and Management of Large Artery Atherosclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2023, 29, 486-500.	0.4	1
268	Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. <i>Medicina (Lithuania)</i> , 2023, 59, 776.	0.8	3
274	Diabetes and Stroke: The Role of Glucose Regulation. , 2023, , 837-855.		0
275	Lipoproteins and Ischemic Stroke in Diabetes. <i>Contemporary Diabetes</i> , 2023, , 503-522.	0.0	0
276	Stroke Therapeutics in the Care of Older Persons. <i>Practical Issues in Geriatrics</i> , 2023, , 349-367.	0.3	0
299	Maternal Stroke. <i>Contemporary Cardiology</i> , 2023, , 197-217.	0.0	0
306	Management of ischaemic stroke survivors in primary care setting: the road to holistic care. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	0
314	Management of lipid abnormalities in metabolic syndrome. , 2024, , 453-461.		0
327	Cerebrovascular Disease and Stroke. , 2024, , 1047-1072.		0